Legato Capital Management LLC Acquires 23,382 Shares of Prestige Consumer Healthcare Inc. $PBH

Legato Capital Management LLC boosted its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 532.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 27,774 shares of the company’s stock after buying an additional 23,382 shares during the quarter. Legato Capital Management LLC’s holdings in Prestige Consumer Healthcare were worth $1,713,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP grew its position in Prestige Consumer Healthcare by 4.8% during the third quarter. Dimensional Fund Advisors LP now owns 2,591,744 shares of the company’s stock valued at $161,723,000 after buying an additional 119,459 shares during the period. Allspring Global Investments Holdings LLC grew its position in Prestige Consumer Healthcare by 1.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,613,460 shares of the company’s stock valued at $98,776,000 after buying an additional 21,085 shares during the period. Bank of America Corp DE grew its position in Prestige Consumer Healthcare by 19.1% during the second quarter. Bank of America Corp DE now owns 721,371 shares of the company’s stock valued at $57,601,000 after buying an additional 115,459 shares during the period. Massachusetts Financial Services Co. MA grew its position in Prestige Consumer Healthcare by 10.2% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 650,793 shares of the company’s stock valued at $40,147,000 after buying an additional 60,496 shares during the period. Finally, Raymond James Financial Inc. grew its position in Prestige Consumer Healthcare by 15.7% during the third quarter. Raymond James Financial Inc. now owns 637,932 shares of the company’s stock valued at $39,807,000 after buying an additional 86,373 shares during the period. 99.95% of the stock is currently owned by institutional investors.

Insider Activity at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 1,207 shares of the business’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the transaction, the vice president owned 42,820 shares of the company’s stock, valued at approximately $2,354,671.80. The trade was a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH opened at $48.02 on Friday. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.57 and a quick ratio of 2.25. Prestige Consumer Healthcare Inc. has a 1-year low of $42.62 and a 1-year high of $87.12. The company has a market capitalization of $2.27 billion, a P/E ratio of 12.28, a P/E/G ratio of 1.54 and a beta of 0.40. The firm’s 50 day simple moving average is $55.97 and its two-hundred day simple moving average is $60.90.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Wednesday, May 13th. The company reported $1.23 EPS for the quarter, missing the consensus estimate of $1.39 by ($0.16). Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The company had revenue of $281.62 million during the quarter, compared to analysts’ expectations of $293.64 million. During the same period last year, the firm posted $1.32 EPS. Prestige Consumer Healthcare’s quarterly revenue was down 5.0% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Research analysts expect that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Zacks Research lowered shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Monday, May 18th. Canaccord Genuity Group cut their target price on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Jefferies Financial Group cut their target price on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research report on Friday, January 30th. Oppenheimer downgraded shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Finally, Weiss Ratings downgraded shares of Prestige Consumer Healthcare from a “hold (c)” rating to a “hold (c-)” rating in a report on Thursday, May 14th. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Prestige Consumer Healthcare presently has an average rating of “Hold” and an average price target of $70.75.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).